← Eichor
Study identifier: NCT05675527 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

PRP for Glenohumeral Osteoarthritis

Condition: Shoulder Osteoarthritis  ·  Sponsor: Hospital for Special Surgery, New York

PhasePhase 4
Planned participants135
Who can joinAll sexes, 18 Years to 100 Years
Healthy volunteersNo

About this study

The glenohumeral joint is the third most common large joint to be affected by OA. Conservative treatments include physical activity, corticosteroid injections, and medications. PRP is an emerging treatment that has shown efficacy in different musculoskeletal conditions. The use of PRP for glenohumeral OA has been described sparingly in the literature but has shown efficacy in a couple studies and case reports. However, all of the previous studies investigating PRP for glenohumeral OA have focused on low-dose PRP preparations (\~3X), and none have compared PRP treatment to saline treatment. This study aims to compare outcomes following single injections of low-dose PRP, high-dose PRP, or saline in patients with glenohumeral osteoarthritis.

This description comes directly from the study's public registry record.

Talk to the study team

Jonathan Kirschner, MD  ·  646-714-6327  ·  kirschnerj@hss.edu

Jennifer Cheng  ·  646-714-6870  ·  chengj@hss.edu

Always discuss trial participation with your own doctor first.

Locations (1)

Hospital for Special SurgeryNew York, New York, United StatesRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT05675527